A Phase 2 interventional study of BMS-663068 400 mg and BMS-663068 800 mg in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 56 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.
Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint analysis, then open label. The reference groups is all open-label.
Arms: 5 (4 BMS-663068 treatment groups and 1 reference group)
Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 254 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Group 1
Drug: BMS-663068 400 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg
Treatment Group 2
Drug: BMS-663068 800 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg
Treatment Group 3
Drug: BMS-663068 600 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg
Treatment Group 4
Drug: BMS-663068 1200 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg
Treatment Group 1 (reference arm)
Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg · Drug: Ritonavir 100 mg · Drug: Atazanavir 300 mg
Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tablets, Oral, 100 mg, Once daily, 96 weeks
Capsules, Oral, 300 mg, Once daily, 96 weeks
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 24 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage confidence intervals (CI). Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest. Intent-To-Treat-Exposed (ITT-E) Population includes all randomized participants who received at least one dose of study treatment.
Time frame: Week 24
Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety population included all participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week 24 included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 24 visit snapshot window.
Time frame: Up to Week 24
Change From Monotherapy Baseline in log10 HIV RNA of the Monotherapy Period
Change from monotherapy Baseline in log10 HIV RNA to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. ITT-E Monotherapy Population comprised of participants that were randomized and participated in the monotherapy sub-study and received at least one dose of FTR Monotherapy. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and up to Day 8 of the monotherapy period
Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA
Maximum decrease from monotherapy Baseline in log10 plasma HIV-1 RNA during monotherapy to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. The data for monotherapy nadir has been presented where nadir represents the maximum decrease from Baseline.
Time frame: Baseline and up to Day 8 of the monotherapy period
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Baseline of combination therapy was assessed to evaluate the antiviral activity of four doses of FTR. Baseline of combination therapy was the Day 1 of the combination therapy. Virologic success or failure was determined using the non-missing viral load value at Baseline of combination therapy. The assessment closest to the window target Study Day was used for the analysis. Only those participants with data available at the specified time points were analyzed.
Time frame: Up to Day 8 of the monotherapy period
Number of Participants With SAE and Discontinuation Due to AEs During Monotherapy Period
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment.
Time frame: Up to Day 8 of the monotherapy period
Change From Monotherapy Baseline in Cluster of Differentiation (CD)4+ and CD8+ T-cell Counts During Monotherapy
Blood was collected and CD4+ and CD8+ cell count assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.
Time frame: Baseline and Day 8
Change From Monotherapy Baseline in CD4+ and CD8+ T-cell Proportion During Monotherapy
Blood was collected and CD4+ and CD8+ proportion assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.
Time frame: Baseline and Day 8
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Primary Study
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage CI. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest.
Time frame: Weeks 48 and 96
Number of Participants With SAE and Discontinuation Due to AEs During Primary Study
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety Population comprised of participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week X (where X = 48 or 96) included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 48 and 96 visit snapshot window.
Time frame: Weeks 48 and 96
Change From Baseline in CD4+ T-cell Count
Blood was collected and CD4+ cell count assessment by flow cytometery was carried out at Baseline (Day 1), Weeks 24, 48 and 96 to evaluate the immunological activity of multiple doses of BMS-663068/GSK3684934. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 24, 48 and 96
Number of Participants With Newly-emergent Genotypic Substitutions at Week 24
Participants who administered antiretroviral (ARV) with virologic failure (VF) were assessed. Genotypic substitution included assessment of Reverse Transcriptase (RT) substitution, Protease Inhibitor (PI) substitution and Integrase RAL substitution as per International Acquired Immune Deficiency Syndrome (AIDS) Society-USA (IAS-USA) list. ITT-E Resistance Tested through Week 24 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 24 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or met the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.
Time frame: Up to Week 24
Number of Participants With Newly-emergent Genotypic Substitutions at Week 48
Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 48 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 48 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.
Time frame: Up to Week 48
Number of Participants With Newly-emergent Genotypic Substitutions at Week 96
Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 96 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 96 Snapshot analysis window. The criteria for resistance tested was participants with virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.
Time frame: Up to Week 96
Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL . The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
Time frame: Baseline and up to Week 24
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
Time frame: Baseline and up to Week 48
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 96
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
Time frame: Baseline and up to Week 96
Participants with Human Immunodeficiency Virus (HIV-1) were randomized in ratio of 1:1:1:1:1 to 5 treatment arms of the study. Four groups with distinct dose of Fostemsavir (FTR, also referred BMS-663068) with Raltegravir (RAL) Tenofovir Disoproxil Fumarate (TDF). There was a reference group with ritonavir (r) boosted atazanavir (ATV), RAL and TDF.
| Milestone | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| Started | 50 | 49 | 51 | 50 | 51 |
| Completed | 33 | 25 | 28 | 22 | 22 |
| Not completed | 17 | 24 | 23 | 28 | 29 |
| Withdrew: Adverse event | 0 | 3 | 0 | 2 | 7 |
| Withdrew: Death | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Continuation criteria not met | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 3 | 7 | 4 | 4 | 2 |
| Withdrew: Lost to follow-up | 5 | 3 | 3 | 8 | 5 |
| Withdrew: Non-compliance with study drug | 1 | 2 | 6 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Sponsor terminated | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 5 | 6 | 7 | 9 |
| Withdrew: Investigator relocating | 0 | 2 | 0 | 3 | 1 |
| Withdrew: Unable to come back for visit | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Prison | 0 | 0 | 1 | 0 | 0 |
| Withdrew: As per exclusion criteria | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Missed end of treatment visit | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adhesion problem | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Early termination | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 24 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage confidence intervals (CI). Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest. Intent-To-Treat-Exposed (ITT-E) Population includes all randomized participants who received at least one dose of study treatment.
| Percentage of Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24 | 80 (66.3 to 90.0) | 69 (54.6 to 81.7) | 76 (62.5 to 87.2) | 72 (57.5 to 83.8) | 75 (60.4 to 85.7) |
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety population included all participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week 24 included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 24 visit snapshot window.
| Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| SAE | 3 | 4 | 4 | 2 | 5 |
| AEs leading to discontinuation | 1 | 2 | 0 | 1 | 2 |
Change from monotherapy Baseline in log10 HIV RNA to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. ITT-E Monotherapy Population comprised of participants that were randomized and participated in the monotherapy sub-study and received at least one dose of FTR Monotherapy. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| log10 c/mL | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| Day 2, n=7, 5, 10, 9 | 0.220 ± 0.1630 | 0.149 ± 0.1820 | 0.126 ± 0.1811 | 0.126 ± 0.4216 |
| Day 5, n=7, 4, 10, 10 | -0.340 ± 0.3185 | -0.811 ± 0.3455 | -0.593 ± 0.2429 | -0.767 ± 0.6388 |
| Day 6, n=7, 5, 10, 10 | -0.530 ± 0.3170 | -1.082 ± 0.3388 | -0.822 ± 0.3076 | -1.053 ± 0.7491 |
| Day 7, n=6, 5, 10, 10 | -0.556 ± 0.4264 | -1.443 ± 0.4484 | -1.086 ± 0.4216 | -1.198 ± 0.6863 |
| Day 8, n=6, 4, 9, 9 | -0.691 ± 0.5380 | -1.372 ± 0.3208 | -1.218 ± 0.3902 | -1.470 ± 0.6570 |
Maximum decrease from monotherapy Baseline in log10 plasma HIV-1 RNA during monotherapy to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. The data for monotherapy nadir has been presented where nadir represents the maximum decrease from Baseline.
| log10 c/mL | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA | -0.770 ± 0.4487 | -1.524 ± 0.3898 | -1.250 ± 0.3818 | -1.399 ± 0.6688 |
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Baseline of combination therapy was assessed to evaluate the antiviral activity of four doses of FTR. Baseline of combination therapy was the Day 1 of the combination therapy. Virologic success or failure was determined using the non-missing viral load value at Baseline of combination therapy. The assessment closest to the window target Study Day was used for the analysis. Only those participants with data available at the specified time points were analyzed.
| Percentage of Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period | 0 (0.0 to 45.9) | 0 (0.0 to 60.2) | 0 (0.0 to 33.6) | 11 (0.3 to 48.2) |
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment.
| Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| SAE | 0 | 0 | 0 | 0 |
| AEs leading to discontinuation | 0 | 0 | 0 | 0 |
Blood was collected and CD4+ and CD8+ cell count assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.
| cells per cubic millimeter | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| CD4+ | 58.4 ± 81.60 | 134.8 ± 25.70 | 71.8 ± 117.68 | 63.4 ± 100.86 |
| CD8+ | 134.2 ± 180.64 | 216.3 ± 215.57 | 188.0 ± 363.58 | 67.6 ± 236.55 |
Blood was collected and CD4+ and CD8+ proportion assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.
| cells per cubic millimeter | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| CD4+ | -0.005 ± 0.0084 | 0.023 ± 0.0299 | 0.008 ± 0.0335 | 0.014 ± 0.0320 |
| CD8+ | -0.003 ± 0.0273 | -0.040 ± 0.0245 | -0.009 ± 0.0465 | -0.021 ± 0.0364 |
Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage CI. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest.
| Percentage of Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| Week 48 | 82 (68.6 to 91.4) | 61 (46.2 to 74.8) | 69 (54.1 to 80.9) | 68 (53.3 to 80.5) | 71 (56.2 to 82.5) |
| Week 96 | 78 (64.0 to 88.5) | 49 (34.4 to 63.7) | 63 (48.1 to 75.9) | 58 (43.2 to 71.8) | 57 (42.2 to 70.7) |
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety Population comprised of participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week X (where X = 48 or 96) included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 48 and 96 visit snapshot window.
| Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| SAE, Week 48 | 3 | 5 | 4 | 2 | 5 |
| SAE, Week 96 | 5 | 7 | 6 | 4 | 7 |
| AEs leading to discontinuation, Week 48 | 1 | 2 | 0 | 1 | 3 |
| AEs leading to discontinuation, Week 96 | 1 | 2 | 0 | 2 | 5 |
Blood was collected and CD4+ cell count assessment by flow cytometery was carried out at Baseline (Day 1), Weeks 24, 48 and 96 to evaluate the immunological activity of multiple doses of BMS-663068/GSK3684934. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Cells per cubic millimeter | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| Week 24, n=41, 38, 48, 42, 40 | 134.3 ± 84.63 | 111.0 ± 123.75 | 109.5 ± 87.20 | 124.5 ± 111.04 | 119.4 ± 142.85 |
| Week 48, n=43, 34, 43, 41, 41 | 199.1 ± 124.24 | 158.7 ± 118.70 | 140.5 ± 97.16 | 155.4 ± 107.06 | 178.7 ± 133.90 |
| Week 96, n=42, 28, 35, 28, 31 | 264.6 ± 147.83 | 210.8 ± 158.03 | 175.7 ± 98.28 | 211.7 ± 151.03 | 250.1 ± 217.54 |
Participants who administered antiretroviral (ARV) with virologic failure (VF) were assessed. Genotypic substitution included assessment of Reverse Transcriptase (RT) substitution, Protease Inhibitor (PI) substitution and Integrase RAL substitution as per International Acquired Immune Deficiency Syndrome (AIDS) Society-USA (IAS-USA) list. ITT-E Resistance Tested through Week 24 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 24 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or met the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.
| Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| PI substitution | 0 | 0 | 0 | 0 | 0 |
| RT substitution | 0 | 0 | 0 | 1 | 0 |
| Integrase substitution | 0 | 0 | 1 | 1 | 0 |
Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 48 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 48 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.
| Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| PI substitution | 1 | 0 | 0 | 1 | 0 |
| RT substitution | 0 | 0 | 0 | 2 | 0 |
| Integrase substitution | 1 | 1 | 1 | 2 | 0 |
Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 96 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 96 Snapshot analysis window. The criteria for resistance tested was participants with virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.
| Participants | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF |
|---|---|---|---|---|---|
| PI substitution | 3 | 1 | 2 | 2 | 0 |
| RT substitution | 2 | 1 | 2 | 2 | 1 |
| Integrase RAL substitution | 2 | 2 | 1 | 3 | 0 |
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL . The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
| IC50 Fold Change | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24 | -2.350 ± 3.4536 | 1014.748 ± 2015.5876 | 101.627 ± 190.4849 | 39.030 ± 55.1119 |
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
| IC50 Fold Change | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48 | -2.624 ± 3.2819 | 586.776 ± 1521.9126 | 81.729 ± 165.4931 | 449.092 ± 647.9828 |
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
| IC50 Fold Change | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF |
|---|---|---|---|---|
| Change From Baseline in IC50 Fold Change Among Participants With VF at Week 96 | 25.480 ± 68.9030 | 419.901 ± 1092.5929 | 46.351 ± 157.9219 | 777.818 ± 1550.8887 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of study treatment (Day 1) until 2117 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FTR/RAL/TDF Total | 3/200 (1.5%) | 35/200 (17.5%) | 163/200 (81.5%) |
| ATV/r/RAL/TDF | 0/51 (0%) | 8/51 (15.7%) | 46/51 (90.2%) |
| Event | FTR/RAL/TDF Total | ATV/r/RAL/TDF |
|---|---|---|
| InfluenzaInfections and infestations | 0/200 | 1/51 |
| PneumoniaInfections and infestations | 0/200 | 1/51 |
| Pyelonephritis acuteInfections and infestations | 0/200 | 1/51 |
| OverdoseInjury, poisoning and procedural complications | 3/200 | 1/51 |
| Ankle fractureInjury, poisoning and procedural complications | 0/200 | 1/51 |
| DiarrhoeaGastrointestinal disorders | 1/200 | 1/51 |
| Abdominal pain upperGastrointestinal disorders | 0/200 | 1/51 |
| MigraineNervous system disorders | 0/200 | 1/51 |
| CholelithiasisHepatobiliary disorders | 0/200 | 1/51 |
| Bone tuberculosisInfections and infestations | 2/200 | 0/51 |
| Event | FTR/RAL/TDF Total | ATV/r/RAL/TDF |
|---|---|---|
| HyperbilirubinaemiaHepatobiliary disorders | 0/200 | 11/51 |
| DiarrhoeaGastrointestinal disorders | 37/200 | 10/51 |
| HeadacheNervous system disorders | 38/200 | 6/51 |
| NasopharyngitisInfections and infestations | 32/200 | 5/51 |
| JaundiceHepatobiliary disorders | 0/200 | 8/51 |
| Urinary tract infectionInfections and infestations | 28/200 | 6/51 |
| Upper respiratory tract infectionInfections and infestations | 27/200 | 7/51 |
| InfluenzaInfections and infestations | 22/200 | 7/51 |
| Ocular icterusHepatobiliary disorders | 1/200 | 7/51 |
| GastroenteritisInfections and infestations | 11/200 | 6/51 |
| Age, Continuous(Years) | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF | Total |
|---|---|---|---|---|---|---|
| Mean | 38.1 ± 8.17 | 38.4 ± 9.49 | 40.1 ± 9.45 | 39.2 ± 11.41 | 39.7 ± 10.63 | 39.1 ± 9.84 |
| Sex: Female, Male(Participants) | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF | Total |
|---|---|---|---|---|---|---|
| Female | 19 | 21 | 22 | 16 | 22 | 100 |
| Male | 31 | 28 | 29 | 34 | 29 | 151 |
| Race/Ethnicity, Customized(Participants) | FTR 400 mg BID/RAL/TDF | FTR 800 mg BID/RAL/TDF | FTR 600 mg QD/RAL/TDF | FTR 1200 mg QD/RAL/TDF | ATV/r/RAL/TDF | Total |
|---|---|---|---|---|---|---|
| African American/African Heritage | 14 | 15 | 16 | 18 | 13 | 76 |
| American Indian Or Alaska Native | 0 | 0 | 1 | 1 | 1 | 3 |
| Asian | 0 | 2 | 0 | 0 | 0 | 2 |
| White | 20 | 19 | 17 | 16 | 23 | 95 |
| Other/Mixed | 16 | 13 | 17 | 15 | 14 | 75 |
Ran from Jul 2011 to primary completion in Feb 2013, 18 months.
Results were first posted in Nov 2018, 5 years 8 months after primary completion.
Of 42 industry-sponsored phase 2 interventional studies under Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 77 studies reached it within 16 months; a quarter within 10 and three quarters within 47.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fostemsavir